IFP Advisors Inc Lowers Position in Aurinia Pharmaceuticals Inc $AUPH

IFP Advisors Inc trimmed its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 6.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 260,034 shares of the biotechnology company’s stock after selling 17,546 shares during the quarter. IFP Advisors Inc owned about 0.19% of Aurinia Pharmaceuticals worth $2,204,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management purchased a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $39,000. DekaBank Deutsche Girozentrale purchased a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $60,000. Xponance Inc. purchased a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $82,000. Finally, Kazazian Asset Management LLC purchased a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $84,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Kevin Tang bought 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the transaction, the director owned 11,029,500 shares in the company, valued at approximately $111,618,540. This trade represents a 9.97% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 1,300,000 shares of company stock worth $13,590,000 over the last 90 days. Insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

AUPH opened at $11.27 on Friday. The company has a 50 day moving average of $12.06 and a two-hundred day moving average of $9.52. Aurinia Pharmaceuticals Inc has a 52-week low of $6.55 and a 52-week high of $13.54. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The company has a market cap of $1.48 billion, a P/E ratio of 26.21 and a beta of 1.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AUPH. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $13.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.